Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis

limma powers differential expression analyses for RNA-sequencing and microarray studies

Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · see citing works

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259 · see citing works

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890 · see citing works

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108 · see citing works

Robust enumeration of cell subsets from tissue expression profiles

Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 12,116 · see citing works

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · see citing works

Statistical significance for genomewide studies

Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692 · see citing works

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · see citing works

Resolving the fibrotic niche of human liver cirrhosis at single-cell level

Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784 · see citing works

GOplot: an R package for visually combining expression data with functional analysis

Walter, W., Sánchez‐Cabo, F., & Ricote, M. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv300 · Cited by 1,760 · see citing works

From NASH to HCC: current concepts and future challenges

Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392 · see citing works

Nrf2 Is a Direct PERK Substrate and Effector of PERK-Dependent Cell Survival

Cullinan, S. B., Zhang, D. D., Hannink, M., Arvisais, E. W., Kaufman, R. J., & Diehl, J. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7198-7209.2003 · Cited by 1,233 · see citing works

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management

McPherson, S., Hardy, T., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.034 · Cited by 1,059 · see citing works

Comparison of RNA-Seq and Microarray in Transcriptome Profiling of Activated T Cells

Zhao, S., Fung‐Leung, W., Bittner, A., Ngo, K., & Liu, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0078644 · Cited by 945 · see citing works

Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease

Lebeaupin, C., Vallée, D., Hazari, Y., Hetz, C. A., Chevet, É., & Bailly‐Maitre, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.008 · Cited by 945 · see citing works

Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients

Bédossa, P., Poitou, C., Veyrie, N., Bouillot, J., Basdevant, A., Paradis, V., Tordjman, J., & Clément, K. (2012) · Hepatology · doi:10.1002/hep.25889 · Cited by 909 · see citing works

Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease

Tebay, L. E., Robertson, H., Durant, S. T., Vitale, S. R., Penning, T. M., Dinkova-Kostova, A. T., & Hayes, J. D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.021 · Cited by 837 · see citing works

A Protein-Truncating <i>HSD17B13</i> Variant and Protection from Chronic Liver Disease

Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827 · see citing works

Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis

Xiong, X., Kuang, H., Ansari, S., Liu, T., Gong, J., Wang, S., Zhao, X.-Y., Ji, Y., Li, C., Guo, L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.028 · Cited by 784 · see citing works

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671 · see citing works

GDF15 mediates the effects of metformin on body weight and energy balance

Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584 · see citing works

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

Krenkel, O., Puengel, T., Govaere, O., Abdallah, A. T., Mossanen, J. C., Kohlhepp, M., Liepelt, A., Lefebvre, E., Luedde, T., Hellerbrand, C., et al. (2018) · Hepatology · doi:10.1002/hep.29544 · Cited by 557 · see citing works

Plasma protein patterns as comprehensive indicators of health

Williams, S. A., Kivimaki, M., Langenberg, C., Hingorani, A. D., Casas, J. P., Bouchard, C., Jonasson, C., Sarzynski, M. A., Shipley, M. J., Alexander, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0665-2 · Cited by 506 · see citing works

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆

Anstee, Q. M., Darlay, R., Cockell, S., Meroni, M., Govaere, O., Tiniakos, D., Burt, A. D., Bedossa, P., Palmer, J., Liu, Y.-L., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.003 · Cited by 499 · see citing works

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview

Parthasarathy, G., Revelo, X. S., & Malhi, H. (2020) · Hepatology Communications · doi:10.1002/hep4.1479 · Cited by 420 · see citing works

Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n‐3 and n‐6 polyunsaturated fatty acids

Arendt, B. M., Comelli, E. M., David, W. L., Lou, W. Y. W., Teterina, A. A., Kim, T., Fung, S. K., Wong, D., McGilvray, I. D., Fischer, S. E., et al. (2015) · Hepatology · doi:10.1002/hep.27695 · Cited by 335 · see citing works

Hepatic Gene Expression Profiles Differentiate Presymptomatic Patients With Mild Versus Severe Nonalcoholic Fatty Liver Disease

Moylan, C. A., Pang, H., Dellinger, A. E., Suzuki, A., Garrett, M. E., Guy, C. D., Murphy, S. K., Ashley‐Koch, A. E., Choi, S. S., Michelotti, G. A., et al. (2013) · Hepatology · doi:10.1002/hep.26661 · Cited by 316 · see citing works

17‐Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease

Ma, Y., Belyaeva, O. V., Brown, P. M., Fujita, K., Valles, K., Karki, S., de Boer, Y. S., Koh, C., Chen, Y., Du, X., et al. (2018) · Hepatology · doi:10.1002/hep.30350 · Cited by 310 · see citing works

Farnesoid X Receptor Responds to Bile Acids and Represses Cholesterol 7α-Hydroxylase Gene (CYP7A1) Transcription

Chiang, J. Y. L., Kimmel, R., Weinberger, C., & Stroup, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.10918 · Cited by 304 · see citing works

Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals

Suppli, M. P., Rigbolt, K. T. G., Veidal, S. S., Heebøll, S., Eriksen, P. L., Demant, M., Bagger, J. I., Nielsen, J. C., Oró, D., Thrane, S. W., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00358.2018 · Cited by 288 · see citing works

Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients

Teufel, A., Itzel, T., Erhart, W., Brosch, M., Wang, X. Y., Kim, Y. O., von Schönfels, W., Herrmann, A., Brückner, S., Stickel, F., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.05.051 · Cited by 229 · see citing works

Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease

Rosso, C., Kazankov, K., Younes, R., Esmaili, S., Marietti, M., Sacco, M., Carli, F., Gaggini, M., Salomone, F., Møller, H. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.031 · Cited by 217 · see citing works

Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease

Hoang, S. A., Oseini, A. M., Feaver, R. E., Cole, B. K., Asgharpour, A., Vincent, R. J., Siddiqui, M. S., Lawson, M. J., Day, N., Taylor, J. M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48746-5 · Cited by 191 · see citing works

Chemokine receptor CCR6-dependent accumulation of γδ T cells in injured liver restricts hepatic inflammation and fibrosis

Hammerich, L., Bangen, J. M., Govaere, O., Zimmermann, H. W., Gassler, N., Huss, S., Liedtke, C., Prinz, I., Lira, S. A., Luedde, T., et al. (2014) · Hepatology · doi:10.1002/hep.26697 · Cited by 190 · see citing works

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

Siddiqui, M. S., Harrison, S. A., Abdelmalek, M. F., Anstee, Q. M., Bédossa, P., Castéra, L., Dimick‐Santos, L., Friedman, S. L., Greene, K., Kleiner, D. E., et al. (2017) · Hepatology · doi:10.1002/hep.29607 · Cited by 165 · see citing works

Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution

Haas, J. T., Vonghia, L., Mogilenko, D. A., Verrijken, A., Molendi-Coste, O., Fleury, S., Deprince, A., Nikitin, A., Woitrain, E., Ducrocq-Geoffroy, L., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0076-1 · Cited by 155 · see citing works

Aldo-keto Reductase Family 1 Member B10 Promotes Cell Survival by Regulating Lipid Synthesis and Eliminating Carbonyls

Wang, C., Yan, R., Luo, D., Watabe, K., Liao, D., & Cao, D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.022897 · Cited by 153 · see citing works

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease

Boyle, M., Tiniakos, D., Schattenberg, J. M., Ratziu, V., Bugianessi, E., Petta, S., Oliveira, C. P., Govaere, O., Younes, R., McPherson, S., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.06.004 · Cited by 140 · see citing works

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

Hardy, T., Wonders, K., Younes, R., Aithal, G. P., Aller, R., Allison, M., Bédossa, P., Betsou, F., Boursier, J., Brosnan, M. J., et al. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106175 · Cited by 138 · see citing works

Growth differentiation factor 15 predicts advanced fibrosis in biopsy‐proven non‐alcoholic fatty liver disease

Koo, B. K., Um, S. H., Seo, D. S., Joo, S. K., Bae, J. M., Park, J. H., Chang, M. S., Kim, J. H., Lee, J., Jeong, W., et al. (2017) · Liver International · doi:10.1111/liv.13587 · Cited by 129 · see citing works

Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis

Wang, M., Gong, Q., Zhang, J., Chen, L., Zhang, Z., Lu, L., Yu, D., Han, Y., Zhang, D., Chen, P., et al. (2017) · Scientific Reports · doi:10.1038/srep43446 · Cited by 124 · see citing works

Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin

Lefebvre, P., Lalloyer, F., Baugé, E., Pawlak, M., Gheeraert, C., Dehondt, H., Vanhoutte, J., Woitrain, E., Hennuyer, N., Mazuy, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92264 · Cited by 117 · see citing works

Gene Expression Profiling Unravels Cancer-Related Hepatic Molecular Signatures in Steatohepatitis but Not in Steatosis

Starmann, J., Fälth, M., Spindelboeck, W., Lanz, K.-L., Lackner, C., Zatloukal, K., Trauner, M. A., & Sültmann, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046584 · Cited by 112 · see citing works

Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis

Ryaboshapkina, M., & Hammar, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-10930-w · Cited by 98 · see citing works

Hepatic GDF15 is regulated by CHOP of the unfolded protein response and alleviates NAFLD progression in obese mice

Li, D., Zhang, H., & Zhong, Y. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.08.096 · Cited by 88 · see citing works

Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification

Dyson, J. K., McPherson, S., & Anstee, Q. M. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201620 · Cited by 78 · see citing works

Transcriptomic Profiling of Obesity-Related Nonalcoholic Steatohepatitis Reveals a Core Set of Fibrosis-Specific Genes

Gerhard, G. S., Legendre, C., Still, C. D., Chu, X., Petrick, A. T., & DiStefano, J. K. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00122 · Cited by 70 · see citing works

All- trans and 9- cis retinoic acid alter rat hepatic stellate cell phenotype differentially

Hellemans, K., Grinko, I., Rombouts, K., Schuppan, D., & Geerts, A. E. (1999) · Gut · doi:10.1136/gut.45.1.134 · Cited by 66 · see citing works

A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis

Parafati, M., Kirby, R. J., Khorasanizadeh, S., Rastinejad, F., & Malany, S. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.033530 · Cited by 61 · see citing works

High‐throughput sequencing identifies aetiology‐dependent differences in ductular reaction in human chronic liver disease

Govaere, O., Cockell, S., Van Haele, M., Wouters, J., Van Delm, W., Van den Eynde, K., Bianchi, A., van Eijsden, R., Van Steenbergen, W., Monbaliu, D., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5228 · Cited by 61 · see citing works

Serum aldo–keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis

Kanno, M., Kawaguchi, K., Honda, M., Horii, R., Takatori, H., Shimakami, T., Kitamura, K., Arai, K., Yamashita, T., Sakai, Y., et al. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01551-3 · Cited by 41 · see citing works

Interleukin‐32β ameliorates metabolic disorder and liver damage in mice fed high‐fat diet

Lee, D. H., Hong, J. E., Hong, J. E., et al. (2015) · Obesity · doi:10.1002/oby.21001 · Cited by 26 · see citing works

SCG10 Expression on Activation of Hepatic Stellate Cells Promotes Cell Motility Through Interference with Microtubules

Paradis, V., Dargère, D., Bieche, Y., Asselah, T., Marcellin, P., Vidaud, M., & Bédossa, P. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100166 · Cited by 14 · see citing works

AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · see citing works

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294 · see citing works

Hepatic fibrosis 2022: Unmet needs and a blueprint for the future

Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430 · see citing works

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Vacca, M., Kamzolas, I., Harder, L. M., Oakley, F., Trautwein, C., Hatting, M., Ross, T., Bernardo, B., Oldenburger, A., Hjuler, S. T., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01043-6 · Cited by 262 · see citing works

Impact of non-invasive biomarkers on hepatology practice: past, present and future

Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224 · see citing works

Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia

Morrow, M. R., Batchuluun, B., Wu, J., Ahmadi, E., Leroux, J. M., Mohammadi-Shemirani, P., Desjardins, E. M., Wang, Z., Tsakiridis, E. E., Lavoie, D. C. T., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.004 · Cited by 199 · see citing works

A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures

Govaere, O., Hasoon, M., Alexander, L., Cockell, S., Tiniakos, D., Ekstedt, M., Schattenberg, J. M., Boursier, J., Bugianesi, E., Ratziu, V., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00775-1 · Cited by 178 · see citing works

Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)

Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158 · see citing works

IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease

Park, J., Zhao, Y., Zhang, F., Zhang, S., Kwong, A. C., Zhang, Y., Hoffmann, H.-H., Bushweller, L., Wu, X., Ashbrook, A. W., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.022 · Cited by 138 · see citing works

Role of bile acids in inflammatory liver diseases

Evangelakos, I., Heeren, J., Verkade, E., & Kuipers, F. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00869-6 · Cited by 121 · see citing works

Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression

Guillot, A., Winkler, M., Silva Afonso, M., Aggarwal, A., Lopez, D., Berger, H., Kohlhepp, M. S., Liu, H., Özdirik, B., Eschrich, J., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000270 · Cited by 116 · see citing works

Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis

Wang, Z.-Y., Keogh, A., Waldt, A., Cuttat, R., Neri, M., Zhu, S., Schuierer, S., Ruchti, A., Crochemore, C., Knehr, J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98806-y · Cited by 103 · see citing works

BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD/NASH

Baboota, R. K., Rawshani, A., Bonnet, L., Li, X., Yang, H., Mardinoglu, A., Tchkonia, T., Kirkland, J. L., Hoffmann, A., Dietrich, A., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00620-x · Cited by 99 · see citing works

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach

Brennan, P. N., Elsharkawy, A. M., Kendall, T. J., Loomba, R., Mann, D. A., & Fallowfield, J. A. (2023) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-023-00796-x · Cited by 68 · see citing works

Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice

Desjardins, E. M., Wu, J., Lavoie, D. C. T., Ahmadi, E., Townsend, L. K., Morrow, M. R., Wang, D., Tsakiridis, E. E., Batchuluun, B., Fayyazi, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101193 · Cited by 33 · see citing works

Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases

Wen, Y., Ma, L., & Ju, C. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100020 · Cited by 31 · see citing works

Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease

Sen, P., Govaere, O., Sinioja, T., McGlinchey, A., Geng, D., Ratziu, V., Bugianesi, E., Schattenberg, J. M., Vidal-Puig, A., Allison, M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104949 · Cited by 28 · see citing works

Effect of distinct ECM microenvironments on the genome-wide chromatin accessibility and gene expression responses of hepatic stellate cells

Jain, I., Brougham-Cook, A., & Underhill, G. H. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.06.018 · Cited by 26 · see citing works

Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors

Cazanave, S. C., Warren, A. D., Pacula, M., Touti, F., Zagorska, A., Gural, N., Huang, E. K., Sherman, S., Cheema, M., Ibarra, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe8939 · Cited by 23 · see citing works

Fibrosis resolution in the mouse liver: Role of Mmp12 and potential role of calpain 1/2

Sato, T., Head, K. Z., Li, J., Dolin, C. E., Wilkey, D., Skirtich, N., Smith, K., McCreary, D. D., Liu, S., Beier, J. I., et al. (2023) · Matrix Biology Plus · doi:10.1016/j.mbplus.2022.100127 · Cited by 14 · see citing works

Myeloid cells contribute to bystander CD8 T cell accumulation in metabolic-associated steatohepatitis and are sufficient for fibrosis

Lebeaupin, C., Donahue, K. L., Lal, S., Christensen, S. M., Asano, S., Wadsworth, M. H., Bound, K., De, S., McMahon, J., Schlerman, F., et al. (2025) · bioRxiv (preprint) · doi:10.64898/2025.12.17.694415

Aldafermin quantitatively improves inflammation in a 24-week clinical trial in patients with nonalcoholic steatohepatitis

Lan, T., Ruiz, L., Liu, W., et al. (2022) · Journal of Hepatology · doi:10.1016/s0168-8278(22)01222-3

Correction of endotoxemia in patients with nonalcoholic steatohepatitis

Собирова, Г. Н., Каримов, М. М., & Alavi, A. (2011) · Medical and Health Science Journal · doi:10.15208/mhsj.2011.180 · Cited by 2 · see citing works

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0

Vairetti, M., Colucci, G., & Ferrigno, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147894 · Cited by 1 · see citing works

Innovative Molecular Targets and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 3.0

Vairetti, M., Colucci, G., & Ferrigno, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074010 · Cited by 4 · see citing works

Sa1567 MRI INTENSITY PATTERNS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND ALCOHOLIC STEATOHEPATITIS

Garrido, D. F., Halegoua-DeMarzio, D. L., Shah, M., et al. (2020) · Gastroenterology · doi:10.1016/s0016-5085(20)31578-x · Cited by 1 · see citing works